The protein biomarker-based test will be used to identify patients at high risk of cancer in order to prioritize them for conventional cancer screening methods.

The work will focus on addressing unmet needs in breast cancer, including the diagnosis and treatment of patients with rare cancer subtypes.

The three-year award from the National Institute for Health and Care Research will support finalization of the test as well as initial validation studies.

The test is the last of three multiplex bloodstream infection panels that the firm has designed for its Liaison Plex molecular testing instrument.

Last week, readers were most interested in a story about the FDA's decision not to appeal a court decision vacating the agency's LDT rule.

The firm is maintaining its full-year guidance and expects to make the acquisition once Lex Diagnostics obtains 510(k) clearance of its system.

Multiple presentations at the meeting discussed the utility of circulating tumor DNA to guide treatment for colorectal cancer.

NEW YORK – New data published in JAMA Internal Medicine on Friday from MD Anderson Cancer Center researchers found that mail-in self-collection kits for human papillomavirus testing more than doubled ...